Novo Nordisk takes Sun Pharma to court over diabetes drug patent
Novo Nordisk, the maker of popular diabetes and weight loss drugs Ozempic and Wegovy, has sued Sun Pharma in Delhi High Court.
The Danish company wants to block Sun from making or selling semaglutide—the key ingredient in these medicines—after a recent court decision let Dr Reddy's export semaglutide but not sell it in India due to ongoing patent issues.
What's at stake?
Novo Nordisk says Sun Pharma is infringing on its Indian patents for semaglutide formulations and delivery devices, which are valid until March 2026.
With the main compound patent already expired, this case could shape how soon Indian companies like Cipla and Mankind can launch their own versions.
Sun Pharma has signaled it's ready to enter the GLP-1 market once the legal dust settles, so all eyes are on how this courtroom battle unfolds.